瑞舒伐他汀对冠脉支架介入术后患者再狭窄率、血脂及IL-8水平的影响

The effect of rosuvastatin on restenosisrate,blood lipid and interleukin-8 level in patients after percutaneous coronary intervention

目的:研究瑞舒伐他汀对冠脉支架介入治疗后患者再狭窄率、血脂及白介素-8(IL-8)水平的影响。方法 :选取2012年3月至2015年3月在武汉市第一医院行冠脉支架介入术(PCI)治疗的急性冠状动脉综合征患者78例,将其随机分为观察组和对照组,每组39例。对照组给予常规治疗及口服辛伐他汀治疗,观察组在常规治疗的基础上给予瑞舒伐他汀口服治疗。比较两组患者术后6个月再狭窄发生率、复发心绞痛率,以及术前、术后血脂[甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白(LDL-C)]和IL-8水平变化。结果:观察组再狭窄发生率为2.56%(1/39),显著低于对照组的15.38%(6/39),差异具有统计学意义(P<0.05)。观察组复发心绞痛率明显低于对照组(P<0.05)。两组患者术后6个月的TC、TG、LDL-C水平比较,差异均无统计学意义(均P>0.05);HDL-C及IL-8水平比较,差异具有统计学意义(P<0.05)。结论:对于急性冠状动脉综合征患者,在常规治疗的基础上给予瑞舒伐他汀较辛伐他汀治疗效果更为显著,能明显降低其PCI术后再狭窄率及复发心绞痛率,改善血脂,并能抑制炎症反应。

Objective： To study the influence of rosuvastatin on restenosis rate, blood lipid and serum inter leukin-8 （IL-8） level in patients after percutaneous coronary intervention （PCI）. Methods：78 patients with acute coronary syndrome （ACS） who underwent PCI in our hospital from March 2012 to March 2015 were selected, and randomly divided into a research group and a control group, with 39 cases in each group. The patients in the control group received routine treatments with the addition of simvastatin, while those in the research group received routine treatments with the addition of rosuvastatin. The restenosis rate and the levels of triglyceride （TC）, total cholesterol （TG）, high density lipoprotein-cholesterol （HDL-C）, low density lipoprotein-cholesterol （LDL-C） and IL-8 in the serum were compared between the two groups. The relative factors of restenosis were analyzed. Results： The restenosis rate was 2. 56% in the research group, which was significantly lower than that in the control group （15.38%） （ P 〈0.05）. The recurrence rate in the research group was lower than that in the control group （ P 〈0.05）. After 6 months of treatment, the levels of TC, TG and LDL-C showed no significant differences between the two groups （ P 〈0.05）, whereas there were significant differences in the levels of HDL-C and IL-8 between the two groups （P 〈0.05）. Conclusion： Rosuvastatin had a better effect than simvastatin for the treatment of ACS, which could improve patients blood lipids, reduce restenosis rate and recurrence rate, and inhibit inflammatory response after PCI.